STAT

Why Democrats reopened the debate about germline gene editing

Democrats in Congress considered lifting a ban on genetically modifying embryos for use in pregnancy. Why now, just months after the CRISPR babies scandal? And what's next?

WASHINGTON — A rogue Chinese scientist stunned the world last year when he announced the birth of genetically modified twin girls, prompting widespread outcry from the broader scientific community and calls for a “global moratorium” on editing human embryos that result in births.

Yet months later, Democrats on Capitol Hill surprised many science policy experts when they attempted to roll back a related, 4-year-old ban on altering the DNA of embryos intended for pregnancies.

To many health policy experts here, and research advocates across the country, the timing — just months after the biggest genome editing scandal in world history — was inexplicable. Several Republicans criticized the proposal by playing up concerns of “maverick bioengineers” operating with little oversight and without ethical norms. And while some scientists supported the

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Pfizer’s DTC Platform, Sandoz’s Feud With A U.K. Trade Group, And More
Pfizer filed a trademark application last month for a website and app providing medical information and mail-order pharmacy and telehealth services to U.S. patients.
STAT1 min read
STAT+: No, Alcohol Isn’t Good For You. Will New Dietary Guidelines Be Shaped More By Health Or Industry Interests?
More and more studies show that alcohol isn't healthy after all. Dietary guidelines are up for revision in 2025, and already, there's debate over research and industry influence.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Plans For Generic Wegovy, Cough Syrup Warnings, And More
Biocon is developing a generic version of Novo Nordisk's Wegovy and is prepared to conduct a clinical trial next year if needed.

Related Books & Audiobooks